Benitec Stock Today

BNTC
 Stock
  

USD 0.17  0.02  10.53%   

Market Performance
0 of 100
Odds Of Distress
Over 57
Benitec Biopharma is trading at 0.17 as of the 7th of December 2022, a -10.53% down since the beginning of the trading day. The stock's open price was 0.19. Benitec Biopharma has over 57 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Benitec Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of November 2022 and ending today, the 7th of December 2022. Click here to learn more.
CUSIP
08205P100
Fiscal Year End
June
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
18th of August 2015
Category
Healthcare
Classification
Health Care
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company was incorporated in 1995 and is headquartered in Hayward, California. Benitec Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 27.98 M outstanding shares of which 165.18 K shares are currently shorted by private and institutional investors with about 0.2 trading days to cover. More on Benitec Biopharma

Moving together with Benitec Biopharma

+0.79EDITEditas Medicine Buyout TrendPairCorr
+0.72HRTXHeron Therapeuti Buyout TrendPairCorr

Moving against Benitec Biopharma

-0.54JPMJPMorgan Chase Sell-off TrendPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Benitec Biopharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Benitec Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Benitec Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Benitec Biopharma generated a negative expected return over the last 90 days
Benitec Biopharma has high historical volatility and very poor performance
Benitec Biopharma has some characteristics of a very speculative penny stock
Benitec Biopharma has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 73 K. Net Loss for the year was (18.21 M) with profit before overhead, payroll, taxes, and interest of 64 K.
Benitec Biopharma currently holds about 4.06 M in cash with (15.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 58.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Insiders who placed huge bets on Benitec Biopharma Inc. earlier this year would be disappointed with the 12 percent drop - Simply Wall St
ChairmanPeter Francis
Fama & French Classification
Average Analyst Recommendation
Analysts covering Benitec Biopharma report their recommendations after researching Benitec Biopharma's financial statements, talking to executives and customers, or listening in on Benitec Biopharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Benitec Biopharma. The Benitec consensus assessment is calculated by taking the average forecast from all of the analysts covering Benitec Biopharma.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Benitec Biopharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
Benitec Biopharma (BNTC) is traded on NASDAQ Exchange in USA and employs 18 people. Benitec Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Benitec Biopharma's market, we take the total number of its shares issued and multiply it by Benitec Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Benitec Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 27.98 M outstanding shares of which 165.18 K shares are currently shorted by private and institutional investors with about 0.2 trading days to cover. Benitec Biopharma currently holds about 4.06 M in cash with (15.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Benitec Biopharma Probability Of Bankruptcy
Ownership
Benitec Biopharma retains a total of 27.98 Million outstanding shares. Over half of Benitec Biopharma outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Benitec Biopharma. Please watch out for any change in the institutional holdings of Benitec Biopharma as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Benitec Ownership Details

Benitec Stock Price Odds Analysis

What are Benitec Biopharma's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Benitec Biopharma jumping above the current price in 90 days from now is about 78.4%. The Benitec Biopharma probability density function shows the probability of Benitec Biopharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.231 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Benitec Biopharma will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Benitec Biopharma is significantly underperforming NYSE Composite.
  Odds Below 0.17HorizonTargetOdds Above 0.17
21.55%90 days
 0.17 
78.40%
Based on a normal probability distribution, the odds of Benitec Biopharma to move above the current price in 90 days from now is about 78.4 (This Benitec Biopharma probability density function shows the probability of Benitec Stock to fall within a particular range of prices over 90 days) .

Benitec Biopharma Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Benitec Biopharma market risk premium is the additional return an investor will receive from holding Benitec Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Benitec Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Benitec Biopharma's alpha and beta are two of the key measurements used to evaluate Benitec Biopharma's performance over the market, the standard measures of volatility play an important role as well.

Benitec Stock Against Markets

Picking the right benchmark for Benitec Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Benitec Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Benitec Biopharma is critical whether you are bullish or bearish towards Benitec Biopharma at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Benitec Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Positions Ratings Now

   

Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Benitec Biopharma Corporate Directors

Benitec Biopharma corporate directors refer to members of a Benitec Biopharma board of directors. The board of directors generally takes responsibility for the Benitec Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Benitec Biopharma's board members must vote for the resolution. The Benitec Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Iain Ross - Non-Executive Independent DirectorProfile
Jerel Banks - Non-Executive DirectorProfile
John Chiplin - Non-Executive Independent DirectorProfile
Megan Boston - Non-Executive DirectorProfile

Invested in Benitec Biopharma?

The danger of trading Benitec Biopharma is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Benitec Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Benitec Biopharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Benitec Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for analysis

When running Benitec Biopharma price analysis, check to measure Benitec Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Benitec Biopharma is operating at the current time. Most of Benitec Biopharma's value examination focuses on studying past and present price action to predict the probability of Benitec Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Benitec Biopharma's price. Additionally, you may evaluate how the addition of Benitec Biopharma to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is Benitec Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.6 M
Quarterly Revenue Growth YOY
(1.00) 
Return On Assets
(0.61) 
Return On Equity
(1.21) 
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Benitec Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.